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Abstract: Socio-economic considerations are included in the regulatory frameworks on genetically
modified organisms (GMOs) of many countries. This is a reflection of an increasing interest in
and recognition of the necessity to consider a broader range of issues when conducting a GMO
risk assessment. At the same time, there are discussions about how socio-economic considerations
can be identified and how their assessment can be carried out. To provide an understanding of
the advances achieved so far, we describe the state of the art of existing biosafety institutional
frameworks, legislation and policies with provisions on socio-economic considerations. We analyse
the scope of the socio-economic considerations that have been included, the methodological options
taken and the role of participatory processes and stakeholders involvement in the GMO-related
decision-making. Since many of the countries that have legislation for assessing socio-economic
considerations lack implementation experience, we provide an analysis of how implementation has
evolved in Norway with the intention to illustrate that the inclusion of socio-economic considerations
might be based on a learning process. Norway was the first country to include broader issues in
its GMO assessment process, and is at present one of the countries with the most experience on
implementation of these issues. Finally, we emphasise that there is a great need for training on how
to perform assessments of socio-economic considerations, as well as reflection on possible ways for
inclusion of participatory processes.
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1. Introduction
There is an increasing international consensus that decision-makers need to consider a broader
range of issues, beyond the environmental and health-related aspects, when assessing the use of
agricultural biotechnologies [1–4]. A broader assessment represents a way to emphasise social
responsibility towards present and future generations [4], and to acknowlegde environmental and
socio-economic aspects while taking into account the possible costs of both regulatory action and
inaction [5]. In the regulatory or academic documents there is at present no general definition of what
the “socio-economic considerations” that should be assessed are. According to the Interorganizational
committee on principles and guidelines for social impact assessment in the US [6], social aspects
consider “the consequences to human populations of any public or private actions that alter the ways in which
people live, work, play, relate to one another, organize to meet their needs and generally cope as members of society.
The term also includes cultural impacts involving changes to the norms, values, and beliefs that guide and
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rationalize their cognition of themselves and their society”. As regards to the dimensions or aspects included
as “socio-economic considerations”, the AdHoc Technical Group on Socio-Economic Considerations
(AHTEG-Sec) of the Convention of Biological Diversity, recognised that there is no single agreed
definition but considered that the scope of the term includes five dimensions: (a) economic; (b) social;
(c) ecological; (d) cultural/traditional/religious/ethical; and (e) human-health related [7].
This inclusion of a broader range of issues is being called for in international frameworks (e.g.,
article 26 of the Cartagena Protocol on Biosafety), European (e.g., [8–10]) and African fora (e.g.,
African Biosafety Model Law), as well as in an increasing number of national regulations on GMOs.
For instance, the Norwegian Gene Technology Act (1993) is the pioneering example. It emphasizes the
need to consider the social utility and contribution to sustainability of GMOs, as well as their direct
and indirect impacts on agricultural practice and the socio-technological context. At the European
level, the aim to take socio-economic considerations into account when making decisions on GMOs
has initiated several activities. These activities includes for instance, the organisation of workshops
on socio-economic considerations (e.g., the International workshop on socio-economic impacts of
GMOs organised by JRC and FAO in November 2011; the European Environmental Agency workshop
“Framing socio-economic assessment in GMO & chemicals regulation” in December 2012), the creation
in 2013 of a working-group including Member States’ experts to address methodological frameworks
for the assessment of socio-economic considerations of GMOs, as well as by the establishment of the
European Socio-Economic Bureau at the Joint Research Center, the publication of national reports
(see, e.g., [11–13]), and the organisation of workshops on socio-economic considerations (e.g., the
International workshop on socio-economic impacts of GMOs organised by JRC and FAO in November
2011; the European Environmental Agency workshop “Framing socio-economic assessment in GMO
& chemicals regulation” in December 2012). Finally, in March 2015 a new directive on GMOs was
approved (Directive (EU) 2015/412), allowing a Member State (or region) to adopt measures restricting
or prohibiting the cultivation in all or part of its territory of a GMO, or of a group of GMOs defined by
crop or trait, based on compelling grounds such as those related to socio-economic impacts, avoidance
of GMOs presence in other products, agricultural policy objectives or public policy (article 1.3).
At the international level, the sixth meeting of the Conference of the Parties serving as the
meeting of the Parties (COP-MOP) to the Cartagena Protocol on Biosafety also recognized the need,
expressed by several Parties, for further guidance when choosing to take into account socio-economic
considerations (decision BS-VI/13 (http://bch.cbd.int/protocol/decisions/?decisionID=13246)), and
recalled operational objective 1.7 of the Strategic Plan of the Cartagena Protocol on Biosafety for the
period 2011–2020. The objective 1.7 aims: “To, on the basis of research and information exchange, provide
relevant guidance on socio-economic considerations that may be taken into account in reaching decisions on the
import of living modified organisms”. For this purpose, the Secretariat of the Convention on Biological
Diversity (CBD) launched several on-line discussions and appointed an Ad Hoc Technical Expert
Group (AHTEG-Sec). This work will be continued following agreement reached at COP-MOP 7 to
reconvene the group of experts to further develop clarity on the issue and to develop an outline for
guidance on the implementation of socio-economic considerations in biosafety decision-making [14].
An increasing number of countries are aiming to include an assessment of a broader range of
issues. However, the need for robust methodologies or frameworks (including criteria, indicators
and comparators) able to capture ex-ante and ex-post socio-economic considerations related to GMO
cultivation, for gaining grounded empirical knowledge, and for appropriate systems for data collection
has been recognised [5,8,15–17]). These gaps have driven, and are at the same time a result of, a
rather contentious debate among biosafety policy-makers and scholars on the desirability of including
such considerations. There are also disagreements on what socio-economic considerations should
be taken into account, both in the regulatory and the research fields (see [18–21] for a review of
the debates on article 26 of the Cartagena Protocol). Contentions have emerged around the scope,
methods and disciplines involved, timing of consideration, baselines and comparators, criteria and
indicators, “endpoints” or targets, the role of public participation and the precautionary principle, and
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the relationship with other fields of knowledge and with other dimensions of risk assessment (mainly
environmental and health-related issues) [12,16,22]. Some of the implications by the selection of specific
approaches in national regulatory frameworks have been reviewed in Spök [12] and Falck-Zepeda [22].
In these two reviews, the number of countries reported was restricted to 12 and 18 countries or regions
respectively, and only a small selection of topics were analysed in detail. An overview commissioned
by the CBD Secretariat [23], which, using a descriptive approach, compiled information from a greater
number of countries (33). The present paper analyses the inclusion of socio-economic considerations in
34 countries. Compared to Spök [12] and Falck-Zepeda [22], our literature study include information
on the implementation experience, a description of the protection goals and considerations taken
into account, a description of the methodological approaches in each country and the role of public
participation in the GMO regulation related to SEC.
The objective of this paper is to describe and analyse the state of the art of existing biosafety
institutional frameworks, legislation and policies with provisions on socio-economic considerations.
The aim is to recognise the advances achieved so far internationally and to reflect on the main challenges
and lessons learnt based on a deeper analysis of a selected case (Norway).
2. Methodology and Information Sources
The present study reviews information regarding the inclusion of socio-economic considerations
for commercial approvals in biosafety decision-making in 34 countries. Countries that have not
included socio-economic considerations are not included in the study. This concerns also countries
that have ratified the Cartagena Protocol but that at present do not have any national biosafety legal
framework that includes socio-economic considerations. The primary sources of information were
the laws, regulations and national policy frameworks, as well as other national official reports, if
any. Most of the information was retrieved using the Biosafety Clearing House established by the
Cartagena Protocol of Biosafety or the National Clearing Houses established by the national Focal
Points of the Protocol, or directly through the official websites for non-signatory countries of the
Protocol (e.g., Argentina).
Additionally, the CBD Secretariat has compiled a series of summaries and reports [23], as well
as national surveys in order to assess how socio-economic considerations are taken into account [24].
These documents have also been reviewed to gather information relative to the state of the art of
the implementation experience of socio-economic considerations in decision-making, as well as on
capacity-building needs. Additionally, a literature review on the implementation of socio-economic
considerations in biosafety decision-making has been conducted. This literature review of policy
reports and academic papers allowed the identification of key contentious issues [14,16,19,22], most
of them also identified by Parties of the CBD as aspects that could contribute to the development
of conceptual clarity on socio-economic considerations [7]: (a) how socio-economic considerations
are defined (including the definition of socio-economic considerations in the analysed regulatory
frameworks, the scope (protection goals, criteria for inclusion and potential impacts taken into
account)); (b) the methodological options (relation between the health and environmental risks and
the socio-economic impact assessment, definition of baselines, factors affecting the methodological
approaches, role of socio-economic expertise in the decision-making, data availability and the inclusion
of participatory approaches) and (c) the role of participatory processes and stakeholders involvement
in the GMO-related decision-making. The results section of the paper is structured following these
categories. With the aim to analyse the practical implementation of socio-economic impact assessments
we then describe the case of Norway. It was the first country to integrate a broader range of issues in
its biosafety regulatory framework.
The regulatory documents were analysed in their original language when it was English, French,
Italian or Spanish, and English translations were used for all other languages. Detailed information
on the documents analysed can be found in Table A1. The first legislation integrating socio-economic
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considerations is the Norwegian Gene Technology Act from 1993 while the last reviewed regulations
are from 2013. The retrieval of the regulations was performed in September 2014.
All the regulatory documents are analysed and classified per type and topics included, and the
classifications we have used are explained below in more detail.
Type of regulatory framework. This classification differentiates between laws, regulations and
guidelines. The classification of the different sources can be found in Table A1. We also recorded the
existence of specific biosafety legislation versus a generic one covering also GMO-related issues.
Implementation experience. For signatory countries of the Cartagena Protocol, we analysed the
experience in adopting socio-economic considerations in decision-making on GMOs using the Second
National Reports on the implementation of the Cartagena Protocol. These reports are based on the
declarations made by the national authorities (see http://bch.cbd.int/protocol/cpb_natreports.shtml).
The national surveys conducted by the CBD Secretariat in 2014 were also used as information
sources [24]. For the case of Argentina (non-signatory), information we retrieved was from the
Ministry of Agriculture webpage.
Definition approach. The description of socio-economic considerations were coded and classified
in prescriptive versus descriptive approaches. The prescriptive approach defines socio-economic
considerations while the descriptive approach identify first a series of protection goals and then list, in
a non-exhaustive manner, potential impacts. Moreover, we recorded if the socioeconomic dimension
included the environment.
Protection goals and socio-economic considerations. We extracted and classified the information
on protection goals and socio-economic considerations using a mix of top-down and bottom-up
approaches. We coded and labeled the protection goals and socio-economic consideration expressed
in the laws, regulations and guidelines. Then, the list of protection goals and socio-economic
considerations was simplified by merging of closely related labels, and classified by using the five
dimensions identified by the AHTEG-Sec [7].
Methodological approaches. We coded the methodological approaches that are described in
the information sources using the same terminology as in the AHTEG-Sec document [7] and by
Falck-Zepeda and Zambrano [21]. We left the list open, so that other methodologies could also
be registered.
Indicators. Indicators are a measure of the progress/harm of specific actions in a time frame. In
some cases (e.g., Norway) the framework establishes guiding questions instead of indicators. We
registered and classified the indicators using the five dimensions defined in the AHTEG-Sec report [7].
Baseline. As in environmental risk assessment, baselines also need to be defined for socio-economic
assessment in order to establish which impacts are considered acceptable, desirable or avoidable are
discussed [13]. We established three options for the use as comparator: conventional agriculture,
organic agriculture and others.
Conditions for approval. In some cases, normative frameworks establish socio-economic
considerations as a condition for approval. In these cases, we chose to take a bottom-up approach,
coding the different issues expressed in the analysed frameworks trying to maintain the original
wording and, when possible, merging similar concepts.
Inclusion of risks and benefits. This aspect analyses if the assessment considers only risk (and cost)
aspects (as it is done in the environmental and health risk assessment) or if it includes also benefits.
Direct and indirect impacts. Direct impacts include impacts that arise as a result of the modifications
to the crop itself while indirect effects are those arising from the effects of the GM crops management
(e.g., co-technologies such as herbicides used with herbicide-resistant crops).
Relation between the socio-economic impact assessment and the environmental and health risk assessment.
The CBD document prepared for the AHTEG-Sec points out that countries can follow different options
when choosing to perform socio-economic assessment for biosafety decision-making [23]. We classified
the documents according to the options described in the CBD document: “Three general routes were
observed: (i) address socio-economic considerations in the risk assessment; (ii) have an independent
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socio-economic considerations assessment; and (iii) evaluate socio-economic considerations through
public participation in the decision-making process” [23].
Level of analysis. This aspect analyses whether the regulatory system will require a specific
assessment for each submission or if it considers other possibilities such as that the assessment needs
to be based on the trait or trait-crop level.
Socio-economic expertise in decision and advisory bodies. This aspect analyses which bodies that are in
charge of conducting the socio-economic assessment and decision-making, and if these bodies (both
for national authorities and advisory committees) have experts with “social sciences” background. We
did not include experts in related areas of expertise such as “agriculture” or “biodiversity”, neither
representatives of Ministries nor other official institutions selected by their affiliation.
Inclusion of the precautionary principle. We classified the countries depending on if they had
included the precautionary principle as a basis for taking decisions in their biosafety frameworks.
Participatory approaches. We took into account three aspects when analysing the role of public
participation in the GMO assessments: public awareness and educational aspects, the access to
information (if final assessments are published or made available to the public upon request), and if
public participation are integrated in the decision-making process.
We carried out the coding and analysis of the data using the computer assisted mixed method
(quantitative and qualitative) data analysis software Dedoose. The coding process was done by one of
the authors. In case of doubts, the coding and classification was discussed with the second author. The
two authors have performed the analysis of the data.
3. Results and Discussion: Inclusion of Socio-Economic Considerations in National
Biosafety Decision-Making
3.1. Basis for Inclusion of Socio-Economic Considerations
In total, there are at present 34 countries that have included socio-economic considerations in
their national biosafety legal frameworks. The geographical distribution of the countries can be found
in Figure 1.
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9 Latin American countries (Argentina, Brazil, Colombia, Costa Rica, Cuba, Mexico, Panama, Uruguay,
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Venezuela). For Asia-Pacific, 6 Asian countries were included (Cambodia, Indonesia, Malaysia,
Pakistan, Philippines, Tajikistan) plus New Zealand. Finally, the laws of 4 European countries were
analysed (France, Italy, Latvia and Norway). Besides these countries, Spök [12] identifies also the
following countries as incorporating socio-economic considerations: Bangladesh, Bhutan, China,
Honduras, India, Lebanon and Syrian Arabic Republic. We did not find specific legislation referring
to socio-economic considerations in these countries except in the case of the Syrian Arabic Republic,
which was not included since the regulatory framework was only found in Arabic. The cases of Belize,
Nigeria and Uganda were also initially analysed, as they all include socio-economic considerations
in their biosafety policies. However, as they do not have approved biosafety legislation yet but only
policy frameworks, they were not included in the final results.
The great majority of the 34 analysed countries have created new legislation for addressing
biosafety, with the exception of Madagascar, Costa Rica and Venezuela. In the case of Madagascar
the legislation is a generic one concerning environmental impact assessment for all kind of activities
(and GMOs are included as requiring this type of assessment). Similarly, in the case of Costa Rica, the
phytosanitary protection regulation includes provisions on GMOs. In Venezuela, GMOs are regulated
under the Environmental Assessment Law and the Law on Genetic Diversity.
According to what the countries themselves have declared, 18 of the analysed countries do not
have experience in the implementation of socio-economic considerations, while 15 of them have at least
some experience in their implementation (See Figure 2). Information on implementation experience
could not be found for Uruguay.
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their territory have been classified as countries with no GMO approval.
Figure 2. Implementation experience of socio-economic considerations (SEC) in genetically modified
organisms (GMO) decision-making.
3.2. Definition of Socio-Economic Considerations in the Legislation of Analysed Countries
3.2.1. Implementation Is Based on Either a Prescriptive or a Descriptive Approach
There are significant differences between countries with regard to how they have defined
socio-economic considerations. For example, Mali and Ethiopia have prescriptive approaches, defining
socio-economic considerations as “any direct or indirect adverse effect that results from a transaction on
the social or cultural conditions, the livelihood or indigenous knowledge systems or technologies of a local
community, including on the economy of the country”. A very similar definition is used by Zambia and
Togo, by describing socio-economic impacts as “any direct or indirect effect to the economy, social or
cultural practices, livelihoods, indigenous knowledge systems or indigenous technologies as a result of the
import, transit, contained use, release or placing on the market of a genetically modified organism or a product
of a genetically modified organism”. Both definitions are very similar to the definition proposed in the
African Model Law on Biosafety. The African Model Law on Biosafety was proposed by the African
negotiators of the Cartagena Protocol on Biosafety aiming to develop a model to provide guidance for
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the development of domestic biosafety laws. The objective of the African Model Law on Biosafety is
“to contribute to ensuring an adequate level of safety for the protection of biological diversity, human
and animal health, socio-economic conditions and ethical values in the making, safe transfer, handling
and use of genetically modified organisms and products of genetically modified organisms resulting
from modern biotechnology”. However, most of the other countries use a descriptive approach,
identifying first a series of protection goals and then listing potential impacts and the main dimensions
to assess (see Tables 1 and 2). This type of approach has been also used in policy reports such as
the one published by the COGEM (Netherlands Commission on Genetic Modification), which states:
“It includes concepts like the benefit to society, the contribution to economy and well-being, health (human rights
and labor conditions), food supply (food security and fair trade), cultural heritage, freedom of choose, security
(environmental and food), biodiversity and environmental quality” [11]. The level of detail also varies widely
among the different regulatory frameworks; some countries’ legislation only mention the need to
assess socio-economic aspects (without specifying which type of impacts the legislation is referring to)
(see, e.g., Brazil, Cuba, Kenya, Mexico and Uruguay), while others have a comprehensive check-list
with the different aspects that may/should be taken into account (see, e.g., Norway).
3.2.2. Scope of the Socio-Economic Considerations Included in the Analysed Legislation: Protection
Goals and Considerations Taken into Account
Most of the regulations that were analysed define first protection goals (21 of the total 34 countries),
which would form the basis for the socio-economic dimensions that should be taken into account
when conducting the assessments. As when conducting an environmental or health assessment, the
first step for a socio-economic assessment is to establish the context for the assessment by identifying
components of the socio-economy that are valued by civil society and/or protected by relevant laws
or policies. This exercise establishes the so-called policy protection goals: components that should
be protected and taken into account to support regulatory decision-making. These protection goals
(or assessment endpoints) can vary between jurisdictions, but their overall aim is to minimise harm.
A thorough problem definition is thereby an essential prerequisite for the operational definition of
these protection goals [25].
These protection goals are then reflected in how the countries define socio-economic
considerations in their biosafety decision-making. In regards to what dimensions are to be included
as socio-economic considerations, Figure 3 shows that most countries do not restrict the definition
of socio-economic considerations exclusively to social and/or economic aspects, but includes also
cultural/ethical aspects, ecologically-related and health aspects not covered by the environmental and
health risk analysis. For instance, in the case of the ecological-related dimension, 16 countries define
protection goals (see Figure 3).
Both countries with GM approvals for commercial purposes and those countries without
approvals have included a variety of protection goals in their regulatory frameworks. Figure 3
illustrates that the number of social, cultural, health- and ecological-related dimension is equally
distributed, while the focus on the economic dimensions is stronger for the countries that have
approved GM crops.
In Figure 4 the socio-economic considerations that have been taken into account in biosafety
decision-making are presented. Figure 4 also differentiates between countries that have approved GM
crops (in gray) and countries without GMOs approvals (in black), showing that both types of countries
consider socio-economic effects in all five dimensions. Argentina is the only country that has limited
the aspects to focus only on the assessment of the economic dimension (see Figure 3).
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Figure 3. Protection goals included in the analysed biosafety regulations.
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Figure 4. SEC taken into account in biosafety decision-making.
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3.3. Methodological Approaches and Use of Criteria and Indicators for Assessing Socio-Economic Considerations
Many of the regulatory frameworks that were analysed do not describe methodological
approaches to use for the assessment of socio-economic considerations. In some cases, there is
only an indication of the methods to use: for instance in Argentina, Burkina Faso, Cameroon and
Senegal it is explicitly noted that the assessment of socio-economic considerations should be based on
cost-benefit principles.
Most of the frameworks do not identify indicators or guiding questions beyond the parameters
described in Figure 4, and there is no suggestion for how to integrate divergent results. Moreover, only
a very restricted number of countries indicate the baselines or the comparators that should be used for
conducting assessments, although the choice of appropriate baselines is crucial for the results of an
assessment. However, some of the countries establish socio-economic considerations as a condition for
approval, mainly linked to the contribution of the GM crop for benefits that are in the public interest
as well its contribution to sustainable development in the country (see Figure 5).
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Figure 5. Conditions for GM cultivation approval related to SEC.
3.3.1. Differences with Regard to Inclusion of Risks and Benefits as Well as Direct and Indirect Effects
Less than 40% of the analysed countries focus only on risks, while the majority of countries
explicitly state that they take into account both risks or costs and benefits within socio-economic
considerations in decision-making. Normally benefits are assessed in relation to risks and/or costs, or
the assessment requires some indicatio of that the GMO contributes with a solution to a social need
or utility (see Figure 6).
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Figure 6. Inclusion of risks and benefits in the analysed biosafety regulatory frameworks.
Of the 34 analysed countries, 15 explicitly state in their legislative framework that socio-economic
impact assessment should include indirect aspects, while the rest of the countries do not specify the
type of socio-economic risks or considerations they are taking into account (see Figure 7).
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Figure 7. Inclusion of indirect impacts in the analysed biosafety regulatory frameworks.
3.3.2. Relat on between the Socio-E onomic Impact Assessment and the Environ ntal and Health
Risk Assessment
None of the countries we have analysed evaluate socio economic considerations only based on
what the CBD documents identify as option (iii): evaluate socio-economic considerations through
public participati n. Only the first two options were found: (a) Socio-economic c iderations were
assessed in the general risk assessment procedure (option (i); or (b) Socio-economic considerations were
evaluated through an i dependent assessment (option (ii) (sometimes consecut ve to the nv ronmental
and health risk ass ssment, others in a parallel but separate pr cess).
Figure 8 summarises the different options taken by the national frameworks that were analysed.
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Figure  8  summarises  the  different  options  taken  by  the  national  frameworks  that  were 
analysed. 
 
Countries that have approved GM crops for cultivation are marked in gray, while countries without approvals are colored 
black. 
F gure 8. Rel tion b tween s cio‐economic conside ations (SEC) assessment and the envi nmental 
and health risk analysis. 
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Countries that have approved GM crops for cultivation are marked in gray, while countries without
approvals are colored black.
Figure 8. Relation between socio-economic considerations (SEC) assessment and the environmental
and health risk analysis.
Table 1 shows that in nine of the analysed countries, socio-economic considerations are defined
as part of the environmental dimension. In these cases, the socio-economic assessment is conducted
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together with the environmental risk assessment. Exceptions are Mexico and Pakistan. Although these
two countries consider socio-economic considerations as part of the environment (see Table 1), they
do establish a distinct and non-integrated assessment for socio-economic and environmental aspects
(see Figure 8).
Table 1. Definitions of “environment” included in SEC frameworks.
Region Country Definition of Environment Article or Section
Africa
Cameroon
Environment: (a) all the natural or artificial elements and the bio-geochemic
equilibriums in which they are involved, as well as the economic, social and
cultural factors which foster the existence, transformation and development
of the environment, living organisms and human activities; (b) natural
abiotic resources such as the surrounding air, surface waters, underground
water, soils, land surface, wildlife and plants, and the interactions between
the elements which all form an integral part of the cultural heritage and
specificities of the landscape under Cameroon’s jurisdiction
Law N˝ 2003/006 of
21 April 2003, chapter II,
sect 5(21)
Ethiopia
...the environmental rights provided under Articles 44 and 92 of the
Constitution of the Federal Democratic Republic of Ethiopia require that
human and animal health, environmental well-being and, in general, the
socio-economic conditions of the country be protected from risks that may
arise from modified organisms
Proclamation 665/2009
on Biosafety, preamble
Namibia
"Environment" means the complex of natural and anthropogenic factors and
elements that are mutually interrelated and affect the ecological equilibrium
and the quality of life, and includes: (a) the natural environment being land,
water, air, all organic and inorganic material and all living organisms; and
(b) the human environment being the landscape and natural, cultural,
historical, aesthetic, economic and social heritage and values
Biosafety Act (Act No.7
of 2006), chapter 1,
definitions
Zambia
“environment” means the aggregate of surrounding objects, conditions and
influences that affect the life and habits of human beings or any other
organism or collection of organisms;
Biosafety Act (Act 10) of
2007, part 1, art. 1
Zimbabwe
“environment” means the aggregate of surrounding objects, conditions and
influences that affect the life and habits of human beings or any other
organism or collection of organisms;
National Biotechnology
Authority Act of 2007,
part 1, art. 2
Asia-Pacific
Pakistan Environment: An ecosystem or habitat, including humans and animals,which is likely to come in contact with a released organism
National Biosafety
Guidelines 2005, app. 12
New
Zealand
environment includes: (a) ecosystems and their constituent parts, including
people and communities; and (b) all natural and physical resources; and (c)
amenity values; and (d) the social, economic, aesthetic, and cultural
conditions which affect the matters stated in paragraphs (a) to (c) or which
are affected by those matters
Hazardous Substances
and New Organisms Act
1996, interpretation
Latin-America
Mexico
Environment: The set of natural and artificial elements or those induced by
man allowing the existence and development of human beings and other
living organisms that interact in a determined space and time, outside the
facility areas, or outside the realms where genetically modified organisms are
used in a confined manner
Law on Biosafety of
GMOs 2005, art. 3(XIX)
Venezuela
Environmental Impact Assessment: Study oriented to predict and assess the
impact of developing an activity on components of the natural and social
environment and to propose preventive, mitigation and corrective measures
in order to verify compliance with environmental provisions contained in
current legislation in the country and to identify environmental parameters
there under may be established for each program or project (own translation)
Normas sobre
Evaluación Ambiental
deActividades
Susceptibles de
Degradarel Ambiente
título I, art 3
3.3.3. Variation in the Level of Assessment and Specifications When Assessing Socio-Economic Considerations
The majority of frameworks do not specify the level of analysis to be taken into account in the
case of socio-economic assessment. Risk assessment is conducted as a response to market applications
on a case-by-case basis. Assessments are conducted at the event-level in most of the cases, and only
in some cases, the legislation specifies that if there is sufficient reason to believe that a GM crop is
safe, there is a possibility to conduct a simplified risk assessment (implying an initial assessment at
the trait level). This is the case in Kenya, for instance. In Norway, socio-economic considerations are
considered on a case-by-case basis. In addition, guiding questions that are trait-specific have been
developed, focusing on herbicide tolerant and insect resistant plants [26,27].
3.3.4. Socio-Economic Expertise in Decision and Advisory Bodies
Only in two of the analysed countries, Argentina and France, is there a specific body that is
designated in the legislation as being in charge of conducting the socio-economic assessment. In the
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case of Argentina, the Direction for Agricultural Markets, under the Ministry of Agriculture, issues a
report on productive and commercial impacts, which complements the assessments for health safety
and environmental risks. In the case of France, the High Council for Biotechnologies comprises two
committees, a scientific committee and another that is in charge of providing recommendations for
economic, ethical and social considerations. In the other cases, it is the national competent authority or
committee in charge of GMOs that takes socio-economic considerations into account. In fact, many
of these countries have at least one member of the committee or national authority that is appointed
based on his or her social science expertise. This is the case in France, Kenya, Namibia, Philippines,
Tajikistan and Zimbabwe.
In other countries, experts on socio-economic considerations are members of the advisory
committees; this is the case, for instance, in Ghana and Norway. In 12 of the analysed countries,
there is no information on the background of the members of the committee or the body providing
socio-economic assessment advice.
The decision-making process varies greatly among the different national regulatory frameworks.
In general, there are two institutional arrangements for making the final decision: (i) it is taken by
the National Authority, which deals directly with the risk assessment or is advised by a technical
body; (ii) the final decision is taken by the Minister responsible (Minister of Agriculture, Minister of
Environment or Minister of Science and Technology), on the advice of the technical bodies and/or
National Authority. The selection of the members of the national authorities and advisory committees
also varies greatly among countries, with members appointed by the responsible ministers, government
or the President.
3.3.5. Other Aspects Related to Socio-Economic Assessment: Inclusion of Precautionary Approaches in
GMO Regulation
The majority of the countries reviewed refer to the precautionary principle or approach as a basis
for taking decisions, although precaution is not taken as a guiding principle in eight of the countries
(see Figure 9).
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Only in Indonesia, Togo and Zambia it is explicitly stated that the precautionary principle can 
also  be  applied  to  socio‐economic  considerations.  In  the  case  of  Costa  Rica,  the  precautionary 
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Figure 9. Use of the precautionary principle as a guiding principle.
Only in Indonesia, Togo and Zambia it is explicitly stated that the precautionary principle can
also be applie to socio-economic considerations. In the case of Costa Rica, the prec utionary rinciple
is linked to the c -existence between GM and organic farming and, in France it also covers consumers’
freedom to choose between GM and non-GM products. In the cases of Burkina Faso and Cameroon
the pr cautionary principle is in roduced in the c text of eval ating alt rnatives to GM crop , as part
of the risk assessment. In the cases of Brazil, Colombia, Gha a and Venezuela, the appl cation of the
precautionary principle is restricted to the environmental risk assessment (including biodiversity risks).
There are different definitions used when referring to the use of the precautionary principle or
approach. While in some countries the emphasis is placed on the right to use preventive measures
in case of suspicion of serious threat or irreversible damage, even in the absence of scientific proof
or evidence (Cameroon, Burkina Faso, Mali or Senegal); in other countries the focus is not placed
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on preventive measures but on the information used for taking decisions by using the formulation
in Table A1 III (on risk assessment) of the Cartagena Protocol of Biosafety: “Provided that lack of
scientific knowledge due to insufficient relevant scientific information or scientific consensus should
not be interpreted as indicating a particular level of risk, or absence of risk, or an acceptable risk”
(e.g., Mexico). In one case, the Philippines, the two approaches coexist in the same regulatory piece. In
other cases, the legislation establishes some limits to or nuances in the application of the precautionary
principle. For example, in the case of Senegal, it establishes the precautionary principle as a guiding
principle and adds: “The authorities must take into account the general principles applicable to all
risk management: the principle of proportionality, the principle of non-discrimination, the principle of
consistency of the measures and the examination of benefits and costs resulting from the approval, as
well as the development/evolution of scientific knowledge” (own translation, Loi 2009/27 portant sur
la Biosécurité, cap IV, art. 4).
In some cases, the precautionary principle is applied together with the prevention principle that
instigates the application of anticipatory measures to prevent negative impacts. In the case of Togo, for
instance, it is explicitly stated that both principles should be applied to potential damaging impacts
on human and animal health, biodiversity, the socio-economic domain and cultural values (Loi de
Biosécurité, art. 6).
3.4. Participatory Approaches in GMO Regulation
A participatory approach in GMO socio-economic assessment may serve different purposes,
ranging from informing and raising public awareness on the technology to be introduced, to the
inclusion and representation of divergent societal opinions so as to increase transparency and
legitimacy in the decision-making process. Public awareness and education are aspects raised by one-third
of the analysed biosafety regulatory frameworks (e.g., Burkina Faso, Cambodia, Colombia, Ghana,
Kenya, Latvia, Namibia, Pakistan, Philippines, Senegal, Tajikistan and Togo). Most of these countries
promote public awareness, aiming to improve the understanding of biosafety issues by providing
information on national policies and on the risks and benefits of modern biotechnology. Some of
the means described for doing so are the publication of guidance documents and other materials
for the general public and through public lectures, seminars and workshops. Moreover, the Togo
Biosafety Law establishes a fee for importers of GM products, which is channeled to fund public
education and awareness activities (art. 91). This is also the case of the Philippines where the fee is
used for building “the capacity of environmental and developmental non-government organizations, people’s
organizations, professional organizations, including industry and other concerned entities to assist in this
capacity-building program shall be enhanced” (Executive order 514/2006, 8.1(d)).
Most of the analysed countries have regulated access to information, by providing for public access
to information on biosafety in general (for instance, by implementing National Biosafety Clearing
Houses), and information on applications for GM crops approvals as well on approved cultivation of
GM crops. In some countries, the information on applications is available to the public upon request
(e.g., Ghana, Kenya, Mali and Senegal), while some fee is also applied in one of the countries (e.g.,
Kenya). Latvia, Italy and France have also implemented a public register of GM fields, which should
be made available to the public. Moreover, the great majority of the analysed countries publish the
final assessments so that the public can consult them. Only in the case of Namibia is the assessment
facilitated upon request of interested parties (see Figure 10).
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Figure 10. Publication of final assessments. 
Public  participation  in  the  decision‐making  process  is  crucial  for  facilitating  transparency  and 
accountability,  and  for  strengthening  public  support  for  the  decisions  taken  regarding  GMOs 
[28,29]. In 31 of the 34 analysed countries, public participation is integrated into decision‐making on 
GMOs, although the role it plays in this process varies widely, as do the detailed provisions to make 
participation  effective.  Information  is  lacking  for  the  case  of  Argentina,  Cuba  and  Pakistan. 
However, important gaps exist on how these provisions are implemented, as well as with regard to 
the weight that the public has in the final decision. Moreover, it was not possible to establish the role 
that public participation plays specifically in the assessment of socio‐economic considerations. 
3.5. The Norwegian Approach for Assessing Broader Issues 
3.5.1. Basis for the Inclusion and Implementation Experience 
The Norwegian Gene Technology Act of 1993 regulates the production and use of GMOs. For a 
GMO to be approved in Norway, the Act requires that the production and use of GMOs take place in 
an  ethically  justifiable  and  socially  acceptable  manner,  in  accordance  with  the  principle  of 
sustainable  development  and  without  adverse  effects  on  human  and  animal  health  and  the 
environment. Section 10, second paragraph, of the Act lays down that GMOs may only be approved 
when  there  is no risk of adverse effects on human or animal health or  the environment, and  that 
considerable weight is to be given to whether the GMO will be of benefit to society and is likely to 
promote sustainable development.   
In Norway the government appointed Biotechnology Advisory Board is responsible for making 
a broad  assessment of GMOs,  and has  a  special  responsibility  for  assessing  sustainability,  social 
benefit and ethical factors. The Board is an independent body consisting of 15 members appointed 
by the Norwegian government. Each member has a background and/or education to ensure that the 
member is competent to discuss questions regarding the use of modern biotechnology. The Board 
gives advice to the Norwegian Environment Agency. 
3.5.2. Implementation of the Socio‐Economic Aspects 
In  2000,  the Board published  a  report  on  how  to  operationalise  the  concepts  of  sustainable 
development, social benefit and ethical and social considerations in the Gene Technology Act [30]. 
Parts  of  this  report  were  included  in  the  appendix  of  the  Regulations  on  Impact  Assessment 
pursuant  to  the  Gene  Technology  Act  (2005).  The  assessment  in  Norway  is  carried  out  by  a 
case‐by‐case approach and covers both direct and indirect well as delayed effects. The precautionary 
principle  is only  linked  to  the  risk  assessment on health  and  the  environment. The  scope of  the 
Regulations on Impact Assessment is to govern the whole process from content to processing of the 
impact  assessments  for GMOs  to  the  investigations  that need  to be  carried out during and  after 
deliberate release, and provides scopes and definitions. The socio‐economic considerations covers 
both potential beneficial factors (favourable) as well as risks or costs (non‐favourable). 
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Figure 10. Use of the precautionary principle as a guiding principle.
Public participation in the decision-making process is crucial for facilitating transparency and
acco ntability, and for strengthening public support for the decisi ns taken re ardi g GMOs [28,29].
In 31 of the 34 alysed countri s, public partici ation is in egrat d into decision-m king on GMOs,
although the role it pl in this process varies w dely, as do the detailed provisions to make
participati n effective. Informat on is lacking for th case of Argentina, Cuba and Pakistan. However,
important gaps ex st on h w these provisions are impl mented, as well as with regard to the weight
that the public has in the final decision. Moreover, t was not possible o establish the role that public
participation plays specifically in the ssessment of socio- conomic c nsiderations.
3.5. The Norwegian Approach for Assessing Broader Issues
3.5.1. Basis for the Inclusion and Implementation Experience
The Norwegian Gene Technology Act of 1993 regulates the production and use of GMOs. For a
GMO to be approved in Norway, the Act requires that the production and use of GMOs take place in
an ethically justifiable and socially acceptable manner, in accordance with the principle of sustainable
development and without adverse effects on human and animal health and the environment. Section
10, second paragraph, of the Act lays down that GMOs may only be approved when there is
no risk of adverse effects on human or animal health or the environment, and that considerable
weight is to be given to whether the GMO will be of benefit to society and is likely to promote
sustainable development.
In Norway the government appointed Biotechnology Advisory Board is responsible for making a
broad assessment of GMOs, and has a special responsibility for assessing sustainability, social benefit
and ethical factors. The Board is an independent body consisting of 15 members appointed by the
Norwegian government. Each member has a background and/or education to ensure that the member
is competent to discuss questions regarding the use of modern biotechnology. The Board gives advice
to the Norwegian Environment Agency.
3.5.2. Implementation of the Socio-Economic Aspects
In 2000, the Board published a report on how to operationalise the concepts of sustainable
development, social benefit and ethical and social considerations in the Gene Technology Act [30].
Parts of this report were included in the appendix of the Regulations on Impact Assessment pursuant to
the Gene Technology Act (2005). The assessment in Norway is carried out by a case-by-case approach
and covers both direct and indirect well as delayed effects. The precautionary principle is only linked to
the risk assessment on health and the environment. The scope of the Regulations on Impact Assessment
is to govern the whole process from content to processing of the impact assessments for GMOs to the
investigations that need to be carried out during and after deliberate release, and provides scopes and
definitions. The socio-economic considerations covers both potential beneficial factors (favourable) as
well as risks or costs (non-favourable).
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There has been an increased stringency and robustness as well as greater scope and depth of detail
in the assessment of GMOs by the Board [31], which can also be found in the revisions carried out in
2006 and 2009 of the report from 2000. Rosendal has performed an analysis of a total of 50 cases from
the period between 1994 to 2005, and she found that between 1993 and 2002, the main aspects that
were emphasised by the Board developed from only considering societal concerns related to pesticide
use to include benefits to the community/public utility, opportunities to reuse seed for farmers, ethics,
and sustainable development. In the period between 2003 and 2005, these issues were extended to
also include access to seeds for food security, effects on global agriculture structures, and North-South
issues of equity.
With the aim of achieving further operationalisation of the provisions related to societal utility
considerations and contribution to sustainable development, the Norwegian Environmental Agency
did in 2009 requested two researchers in the field for a report on how and to what extent marketing
applications for GMOs fulfill the criteria of sustainable development and societal utility in the
Norwegian Gene Technology Act [17,31,32]. The authors, Rosendal and Myhr, identified four objectives
for this report: (a) elaborate how the Norwegian authorities can use the procedures implemented in the
EU system; (b) discuss how the concepts of sustainable development and societal utility can be applied
in a broader sense; (c) evaluate the information provided in two given GMO marketing applications,
with a focus on the adequacy of the supplemented information; and (d) develop recommendations
concerning the assessment of sustainable development and societal utility.
In the two GMO marketing applications that were analysed (see Table 2), the authors of the
report found that the information supplied by the applicants was found to be of high relevance when
assessing impact on global impact and ecological limits, while no information was found related to
basic human needs, distribution between generations, distribution between rich and poor countries,
and economic growth. The checklist used for the analysis of two marketing applications is found in
appendix 4 of the impact assessment pursuant to the Norwegian Gene Technology Act.
Table 2. Available and lacking information for conducting assessment of societal utility and
contribution to sustainable development, following the Norwegian Gene Technology Act (adapted
from Myhr and Rosendal [17]).
Checklist in Appendix 4 of the
Regulations on Impact Assessment
Pursuant to the Gene Technology Act.
Available Information Found in
Applications That Can be Used for
Answering Questions in the Checklist.
Information Lacking in Applications that
Concerns the Questions in the Checklist
Global impacts
Persistence, invasiveness, possible
population and fitness changes introduced
in the GMPPotential for gene transfer
Changes in biogeochemical
processesChanges due to cultivation
patternsEffects on water and energy
balanceLatency/cumulative effects
Ecological limits
Interaction between GMP and target
organismsInteractions between GMO and
non-target organisms
Impacts on socio-ecological relationships
Basic human needs Benefits for healthToxicity and allergenicity Latency/cumulative effectsFood securityissues
Distribution between generations Not found
Latency/cumulative effectsInfluence by
scientific innovationsTrade-off between
utility and risk
Distribution between rich and
poorer countries Not found
Adequacy for meeting problems in poor
countries and especially for small-scale
farmers
Economic growth Not found
Latency/cumulative effectsTrade off
between short term economic growth versus
potential long term adverse effects
When assessing the adequacy of the supplemented information, the authors encountered problems
due to confidentiality restrictions. Furthermore, a substantial number of the supplied references
pointed back to the applicants’ own research departments and therefore lacked peer-review. For wider
concerns that include any potential effects on socio-ecological relationships, the assessed applications
provided little or no relevant information to be used by Norwegian administrative staff to process
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applications. The authors also assessed whether the two applications to market GMOs fulfilled the
criteria of societal utility. Societal utility is closely linked to these four criteria, but is a complicated
concept that may require many points to be considered. These would include, for example, an
assessment of whether the technology is beneficial to small or large farms, whether the technology is
likely to have any effect on employment, food security, landscape aesthetics, or human and animal
health and welfare, and an assessment of who will benefit from the technology. The authors conclude
that the applicants had carried out little research to identify how GM crops might contribute to
sustainability and societal utility around the world [17].
3.5.3. Methodological Approaches and Use of Criteria and Indicators
The Norwegian Environment Agency did in 2010/2011 asked the Board to carry out a project
aimed at translating the concepts of sustainable development, social benefit and ethics in the Gene
Technology Act. Insect-resistant genetically modified plants (2011) and herbicide-resistant plants
(2013) were chosen as case studies. The Agency’s intention was to develop guidelines that could be
used by administrative staff to process applications for approval of such GMOs pursuant to the Gene
Technology Act. In both projects, scientists from different scientific disciplines and institutions in
Norway contributed as ad-hoc experts. The parameters that were elaborated by the project included
environmental, societal and economical issues (see Table 3). Questions that could be asked were
elaborated in further detail in the reports [26,27].
Table 3. Parameters and questions to applicants included in the guidelines elaborated by the Norwegian
Biotechnology Advisory Board for conducting SEC assessments. Adapted from the Norwegian
Biotechnology Advisory Board [26,27].
Parameter Questions to Applicants
Environment/Ecology
On the GM plant: characterization, gene flow, interaction between plant and
the environment, preservation of biodiversity, comparison with
control plants
On the herbicide/Bt toxin: characterization, effects of altered use,
development of resistance
Soil, water, energy and climate
Society/Economy
The right to sufficient, safe and healthy food (food safety, security
and quality)
Animal health and welfare (feed quality)
Living conditions and profitability for the farmers who cultivate GM plants,
in the short term (less than 5 years) and in the long term (more than
20 years) Health and safety, contracts and framework conditions,
employment, developments of costs and incomes, agronomic factors, the
right to seed, ownership rights etc.
Plant genetic resources for food and agriculture
Independent risk research
Freedom to choose agricultural system in the future
When assessing applications for import and use of GMOs in Norway, the Board now uses the
points described in Table 3, and in most cases on GM crops they find there is a lack of information with
regard to these broader issues and asks the applicants to answer the questions as elaborated in the
reports. The reason behind the increased stringency in the Norwegian assessment of broader issues
can hence be due to that this has been a learning process both for the Board and the Agency. The
assessments done by Board are made public and are published on their homepage.
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3.5.4. Participatory Approaches
Norway has regulated access to information, by providing for public access to information on
applications for GM crops approvals. Besides the Board, it is possible both for individuals and for
both research/academic institutions and non-governmental organizations to contribute with inputs as
comments and statements during the assessment period. It is the Norwegian Environment Agency
that makes this information, most often summaries of applications, available through homepage and
by using mailing lists. The Board does also have access to the inputs provided through the public
access. One problem for public participation is that there is not possible to have access to the whole
applications due to confidentiality closures [16].
4. Discussion: Opportunities for and Challenges to the Inclusion of Socio-Economic Considerations
The review of the literature and the analysis of the national legislative frameworks show that
there is a high interest in the inclusion and implementation of socio-economic considerations in
national biosafety regulations. There are differences in approaches and policy goals, resulting, e.g., in
a high diversity in the choice of indicators and parameters to be assessed. The case study of Norway
points out that the inclusion and implementation of socio-economic considerations may be based on a
learning process.
4.1. Methodological Issues and Approaches Taken
The review reveals that there are significant differences in how socio-economic considerations are
integrated into and assessed in the studied national normative frameworks. The main differences are
related to the status of the regulations and approach used (prescriptive versus descriptive formulations
of what socio-economic considerations refer to, the inclusion of only risks versus assessments
integrating both risks and benefits, or assessments taking only into account direct effects versus the
ones that also integrate the assessment of the co-technologies used in conjunction with the GM crop).
At the same time, the research has made explicit that the inclusion of socio-economic
considerations responds to a diversity of national policy goals, which can partially explain the
differences in framing, criteria and indicators between the different countries. The research has
also revealed the importance of identification of protection goals in framing of the socio-economic
assessment in order to achieve an efficient and transparent assessment. The case study on Norway also
illustrates that making the protection goals explicit and consequently developing a framework with
corresponding questions [26,27] can, besides increasing the efficiency, also help in gaining credibility.
This credibility is achieved by providing transparency and being open for public scrutiny of both the
specific questions used in the assessment and their value-based background (e.g., protection goals).
A second interesting feature is the wide inclusion of health and environmental-related
considerations as part of the socio-economic assessment, and the integration of socio-economic aspects
in the definition of “environment” in a significant number of the analysed countries, blurring the
separation between these dimensions that is traditionally demarcated by the risk assessment. This is
also found in the Norwegian case where the environment is considered in a much broader context to
include aspects as preservation of biodiversity, and impacts on soil, water, energy and climate. The
inclusion of environmental aspects may vary and be further developed or removed with experience
both in Norway and in other countries.
4.2. Need for More Empirical Data
There is a need for empirical research for providing data that can be used for assessing
socio-economic considerations. As illustrated in the Norwegian case, the information in applications
is provided for answering issues of relevance for environmental and health risk assessment, hence
only some of the information can be used for assessing socio-economic considerations [17]. Another
challenge is that data from one area may not be directly applicable in another country, or even in
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another area of the same country with different socio-economic characteristics, requiring a reflection
on the significance of the data and the framework and methods used in the context assessment of an
GMO application [16,18].
4.3. Values and Public Participation
Natural scientists from research institutions and representatives of the biotechnology industry
have often dominated the debates concerning risk issues, framing them as purely technical issues [33],
while leaving aside holistic arguments (see, e.g., Walls et al. [34] as an example of how the latter
type of arguments (e.g., concern for the implication for landscape and culture embedded in the
agricultural system or for the growing dominance of multinational corporations in the life sciences)
were marginalised in New Zealand’s debate on GMOs. Jensen et al. [35] have applied the concept of
a “risk window” to illustrate that risk assessments frame the world through a “risk window” that
only makes visible what has been predefined as a relevant risk. The size and structure of this window
is determined by value judgments about what is considered relevant as adverse effects identified in
the process by stakeholders. This is because stakeholders use different conceptual frameworks in
their identification of the values deemed to be important in risk governance of GM crops [36]. The
difficulty in making transparent normative values can be illustrated by for example the discussion
about the appropriate comparators that could serve as baselines for assessing the impacts of GM
crop introduction.
It may be expected that stakeholders will also use different conceptual frameworks for how to
approach and for acknowledging empirical research and data on socio-economic considerations. It
is therefore important that normative values (or policy goals) are made explicit and that debates on
values includes public participation. Further work needs to be conducted on how to interweave
expert and stakeholder inputs and forms of values and knowledge. One example is provided by
the Norwegian case, where members of the Board, scientists and stakeholders were involved in the
identification of parameters and questions to be included in the guidelines for conducting assessment
of sustainability [26,27].
4.4. The Precautionary Principle
The precautionary principle/approach is often linked to the regulation of environmental risks in
general. When it comes to biosafety legislation 14 of the 34 countries analysed connect the principle to
environmental risks. However, precaution is explicitly applied to socio-economic considerations in
only 3 of the total 34 countries examined, extending the traditional implementation of the principle
to the wider governance of science, innovation and trade [33]. The link between the environmental
application of the precautionary principle and the socio-economic assessment is in fact strengthened
by the European Environmental Agency working definition of the precautionary principle [37],
which establishes that an appropriate implementation of the precautionary principle should involve
a well-conceived socio-economic assessment, aiming at more responsible and socially relevant
innovations by addressing the limitations associated with current decision-making by broadening the
issues assessed, integrating public concerns and providing an assessment of alternative options [5].
5. Conclusions: Needs and Recommendations
The review has pointed out that there are challenges related to achieving an effective and
systematic implementation of socio-economic considerations in biosafety regulations. For instance,
very few of the analysed regulations establish robust methodologies during the processes of framing,
data gathering, assessment and decision-making related to socio-economic considerations. In addition,
there are uncertainties associated with socio-economics since the respective scientific evidence and
data remain insufficient, inconclusive or uncertain. There is therefore a need for both more empirical
data and for competence in on how to perform assessments of socio-economic considerations. The
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case study of Norway shows that one of the outcomes by experience is a greater scope and depth of
detail in the assessment of GMOs.
It is necessary to make explicit the normative values during the assessment of socio-economic
consideration and in the decision-making phases. The implementation of socio-economic assessments,
in most of the cases, would result in contradictory or divergent results (not only between different
socio-economic aspects but also between socio-economic assessment and the environmental and health
risk assessment), according to the framing used, the different assessment endpoints, or to the applied
methods. Thus, it is difficult to arrive at unanimous overall conclusions, creating a more demanding
need for transparency, openness and accuracy in the communication of this process.
There is also a need to characterize the different roles played by stakeholders in the analysed
regulatory frameworks at different phases of the assessment: e.g., at the beginning of the process
so as to frame the issues, during the assessments so as to provide data or at the end of the process
for reviewing conclusions and providing opinions, as well as on the possible means of participation
and/or consultation.
Acknowledgments: Rosa Binimelis currently holds a Beatriu de Pinós contract funded by the “Comissionat per a
Universitats i Recerca del Departament d’Innovació, Universitats i Empresa de la Generalitat de Catalunya” and
the COFUND programme-Marie Curie Actions under the FP7 of the European Communities.
Author Contributions: Rosa Binimelis did the search of legislative documents, and performed the coding and
classification of the data using the programme Dedoose. Both authors performed the analysis of the data.
Rosa Binimelis led the drafting of the paper, with Anne Ingeborg Myhr leading the section on the Norwegian case
and contributing to the manuscript with text and comments, supporting references and feedback throughout an
iterative process involving several rounds. All authors have read and approved the final manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix
Table A1. Consulted laws, regulations or guidelines.
Country Analysed Documents Type of Document
Argentina Resolución SAGYP n
˝ 510/2011 of 17th August 2011 Regulation
Resolución SAGYP n˝ 763/2011 of 17th August 2011 Regulation
Brazil
Law No. 11105, 24th March 2005 Law
Decree No. 5,591, 22nd November 2005 (revised version 18th January 2006) Regulation
Burkina Fasso Loi N˝ 005-2006/AN du 4 Mai 2006 portant regime de securit en matiere de biotechnologie Law
Cambodia
Law on Biosafety promulgated on 15th February 2008 (unofficial translation) Law
Sub-decree on Mechanisms and Procedures for Implementing the Law on Biosafety
(unofficial translation)
Regulation
Cameroon Law N˝ 2003/006 of 21 April 2003 to lay down safety regulations governing modern
biotechnology in Cameroon
Law
Colombia Decreto na 4525 de 6 de diciembre de 2005 por el cual se reglamenta la Ley 740 de 2002 Regulation
Costa Rica
Reglamento a la Ley de Protección Fitosanitaria (N˝ 26921-MAG), 2008 Regulation
Reglamento para el Desarrollo, Promoción y Fomento de la Actividad Agropecuaria
Orgánica (Decreto 35242-MAG-H-MEIC), 2008
Regulation
Cuba Reglamento para el otorgamiento de la autorización de seguridad biologica
(Resolución 180 2007)
Regulation
Ethiopia
Proclamation 665/2009 on Biosafety Law
Directive No. 01/ 2009 issued to determine the contents of applications for undertaking
transactions involving modified organisms
Regulation
Directive No. 02/ 2009 issued to determine Risk Assessment Parameters for
modified organisms
Regulation
France
LOI n˝ 2008-595 du 25 juin 2008 relative aux organismes génétiquement modifiés
(NOR: DEVX0771876L; version consolidée au 19 juin 2014)
Law
Code de l'environnement Law
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Ghana
Biosafety Act (No. 831), 2011 Law
Biosafety (Management of Biotechnology) Regulations, 2007 (Legislative Instrument 1887) Regulation
Indonesia Regulation of the Government of the Republic Indonesia Number 21 on Biosafety of
Genetically Engineered Product, 2005
Regulation
Italy
Decreto Legislativo 8 luglio 2003, n. 224. Attuazione della direttiva 2001/18/CE
concernente l'emissione deliberata nell'ambiente di organismi geneticamente modificati
Regulation
Decreto Legislativo 21 marzo 2005, n. 70. "Disposizioni sanzionatorie per le violazioni dei
regolamenti (CE) numeri 1829/2003 e 1830/2003, relativi agli alimenti ed ai mangimi
geneticamente modificati
Regulation
Kenya Biosafety Act No. 2, 2009 (revised version 2012) Law
Latvia
Law On Circulation of Genetically Modified Organisms, 2007 (text consolidated by Valsts
valodas centrs (State Language Centre), 2013)
Law
By-law of the Supervision Council for Genetically Modified Organisms (text consolidated
by Valsts valodas centrs (State Language Centre), 2013)
Law
Regulation No. 453 adopted 19 May 2009. Regulations Regarding the State Fee for
Preparation of the Risk Assessment’s Opinion of Genetically Modified Organisms Regulation
Regulation No. 457, adopted 26 May 2009. Regulations Regarding the Procedures for the
Release into the Environment or Placing on the Market of Genetically Modified Organisms,
the Procedures for Monitoring and Issuance of a Permit, as well as the Procedures for
Providing Information Regarding Circulation of Genetically Modified Organisms and
Public Involvement in the Decision Taking Process
Regulation
Regulation No. 1078, adopted 22 December 2008. Methodology for the Risk Assessment of
Genetically Modified Organisms
Regulation
Madagascar Decret N˝ 99-954 du 15 decembre 1999 modifié par le décret n˝ 2004-167 du 03 février 2004
relatif à la mise en compatibilité des investissements avec l’environnement (MECIE)
Regulation
Malaysia Biosafety Act, 28th 28 August 2007 Law
Biosafety (Approval and Notifcation) Regulations 2010 Regulation
Mali Loi n˝08-042/AN – RM du 1er decembre 2008 relative à la sécurité en Biotechnologie en
République du Mali
Law
Mauritius The Genetically Modified Organisms Act 2004; Act No. 3 of 2004 Law
México
Ley de Bioseguridad de Organismos Genéticamente Modificados, de 18 de marzo de 2005 Law
Reglamento de la Ley de Bioseguridad de Organismos Genéticamente Modificados, de 19
de marzo de 2008 Regulation
Namibia Biosafety Act (Act No.7 of 2006), 30th December 2006 Law
New Zealand
Hazardous Substances and New Organisms Act, 10th June 1996 (reprint as at
1st January 2014) Law
Biosecurity Law Reform Act No 73 of 17th September 2012 Law
Norway
Act relating to the production and use of genetically modified organisms (Gene
Technology Act)Act of 2 April 1993 No. 38 with subsequent amendments, most recently by
Act of 17 June 2005 No. 79
Law
Regulations relating to impact assessment pursuant to the Gene Technology Act laid down
by Royal Decree of 16 December 2005 and annexes 1 to 4 Regulation
Sustainability, Benefit to the Community and Ethics in the Assessment of Genetically
Modified Organisms: Implementation of the Concepts set out in Sections 1 and 10 of the
Norwegian Gene Technology Act. Opinion by the Norwegian Biotechnology
Advisory Board.
Guidelines
Pakistan
Pakistan Biosafety Rules, of 26th April 2005 Law
National Biosafety Guidelines 2005, Notification No. F.2 (7)95-Bio Guidelines
Panama
Ley 48 de 2002 que crea la Comisión Nacional de Bioseguridad para los Organismos
Modificados Genéticamente y dicta otras disposiciones Law
Decreto-Ley 11 de 2006 que crea la autoridad panameña de seguridad de alimentos y dicta
otras disposiciones Law
Philippines
Executive Order No. 514 establishing the national biosafety framework, prescribing
guidelines for its implementation, strengthening the national committee on biosafety of
The Philippines, and for other purposes
Regulation
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Senegal
Loi n˝ 2009-27 du 8 juillet 2009 portant sur la Biosécurité Law
Décret n˝ 2009-1408 du 23 décembre 2009 portant missions, organisation et
fonctionnement du Comité National de Biosécurité (CNB) Regulation
Décret n˝ 2009-1409 du 23 décembre 2009 portant missions, organisation et
fonctionnement de l’Autorité Nationale de Biosécurité (ANB) Regulation
South Africa
Genetically Modified Organisms Act 1997 (Act No. 15, 1997) Law
Genetically Modified Organisms Amendment (Act No. 23 of 2006) Law
Tajikistan Law on Biological Safety Law
National Biosafety Framework of the Republic of Tajikistan. Safarov N., Novikova
T.,Idrisova A. et al. Dushanbe: National Biodiversity and Biosafety Center. 2004. - P.66
Guidelines
Togo Loi n˝ 2009-001sur la prévention des risques biotechnologiques Law
Uruguay Decreto N˝ 353/008, 2008 Regulation
Venezuela
Ley de Gestión de la Diversidad Biológica, de 1 de diciembre de 2008 Law
Normas sobre Evaluacion Ambiental de Actividades Susceptibles de
Degradar el Ambiente Regulation
Decreto n˝ 4334, mediante el cual se dispone que la Comisión Nacional de Bioseguridad,
como organismo técnico-científico, asesorará al Ejecutivo Nacional en las actividades que
en él se señalan. Decreto No. 1.257, de 13 de marzo de 1996
Regulation
Zambia Biosafety Act (Act 10) of 24th April 2007 Law
Zimbabwe National Biotechnology Authority Act [Chapter 14:31], Act 3/2006 Law
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